For the Inventor, By the Inventor

Enter assignee name

Rahway, NJ, United States of America

Intervet Inc.

USPTO Granted Patents = 272

% Expired Patents = 11.0

EPO Patents = 1

Trademarks = 133

Forward Citations = 392

Loading Chart...

Loading Chart...

343 inventors (with patents filed for the assignee):

Mohamad A Morsey (32 out of 40 patents)

Ian Tarpey (24 out of 26 patents)

Yuanzheng Zhang (23 out of 23 patents)

4. Antonius Arnoldus Christiaan Jacobs (16 out of 28 patents)

5. Michael Berger (14 out of 14 patents)

6. Kevin O'Connell (13 out of 14 patents)

7. Keith A Freehauf (13 out of 21 patents)

8. Anja Regina Heckeroth (12 out of 12 patents)

9. Carla Christina Schrier (12 out of 28 patents)

10. Hartmut Zoller (9 out of 9 patents)

11. Annie Flochlay-Sigognault (9 out of 9 patents)

12. Stephanie M Cook (9 out of 11 patents)

13. Maarten Hendrik Witvliet (8 out of 11 patents)

14. Jürgen Lutz (8 out of 8 patents)

15. Paulus Jacobus Antonius Sondermeijer (8 out of 10 patents)

Core Competencies:

Veterinary

Vaccines

Antibodies

Pharmaceuticals

Antimicrobial

Parasite Control

Canine Health

Swine Health

Aquaculture

Infectious Diseases

Immunization

Disease Prevention

272 patents: Sort by Forward Citations

1. 12721885 - A NOVEL VACCINE AGAINST HEAMOPHILUS PARASUIS (2026-09-01),

2. 12721839 - Soft chewable veterinary dosage form (2026-09-01),

3. 12703751 - CANINIZED RAT ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA (2026-08-11),

4. 12703706 - Anthelmintic compounds comprising a thienopyridine structure (2026-08-11),

5. 12697323 - Implantable isoxazoline pharmaceutical compositions and uses thereof (2026-08-04),

6. 12692316 - ANTIBODIES TO CANINE INTERLEUKIN-4 RECEPTOR ALPHA (2026-07-28),

7. 12692233 - Anthelmintic compounds comprising a pyridine structure (2026-07-28),

8. 12686721 - Bispecific Caninized Antibodies and Bispecific Binding Partners for Treating Atopic Dermatitis (2026-07-21),

9. 12655090 - Cyclopropylamide compounds against parasites in fish (2026-06-16),

10. 12653788 - Pharmaceutical composition of a pyrazole compound dispersed in a polymer matrix (2026-06-16),

11. 12648991 - Oral respiratory vaccine (2026-06-09),

12. 12636359 - SWINE INFLUENZA A VIRUS VACCINE COMPRISING TWO DISTINCT RNA REPLICON PARTICLES (2026-05-26),

13. 12630640 - Bispecific Caninized Antibodies for Treating Atopic Dermatitis (2026-05-19),

14. 12630592 - SWINE INFLUENZA A VIRUS VACCINE COMPRISING A NUCLEIC ACID CONSTRUCT HAVING A SPECIFIC ORDER OF GENES (2026-05-19),

15. 12630517 - Process for preparing large size isoxazoline particles (2026-05-19),

Company Overview

Intervet Inc., based in Rahway, NJ, specializes in the development and manufacturing of veterinary vaccines and pharmaceuticals. The company focuses on enhancing animal health through innovative solutions, particularly in the areas of vaccines, antibodies, and antimicrobial products. Intervet's expertise extends to parasite control and health management for various species, including canines and swine. By leveraging advanced research and technology, Intervet aims to improve the well-being of animals and support the veterinary community.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

272 Patents

#3 in Rahway, NJ

#77 in New Jersey

#1,597 in US

#3,232 in the World

Rahway, NJ, United States of America

Intervet Inc.

Forward Citations = 392

343 inventors:

Mohamad A Morsey (32 out of 40 patents)

Ian Tarpey (24 out of 26 patents)

Yuanzheng Zhang (23 out of 23 patents)

4. Antonius Arnoldus Christiaan Jacobs (16 out of 28 patents)

5. Michael Berger (14 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Intervet Inc.. Retrieved from https://idiyas.com/company/intervet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…